Seeing Is Believing

Currently out of the existing stock ratings of Scott Henry, 75 are a BUY (82.42%), 16 are a HOLD (17.58%).
Analyst Scott Henry, currently employed at ALLIANCE GLOBAL PARTNERS, carries an average stock price target met ratio of 54.31% that have a potential upside of 51.18% achieved within 327 days. Previously, Scott Henry worked at ROTH.
Scott Henry’s has documented 182 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VVOS, Vivos Therapeutics at 19-Nov-2024.
Analyst best performing recommendations are on INVO (INVO BIOSCIENCE).
The best stock recommendation documented was for LGND (LIGAND PHARMACEUTICALS) at 2/4/2021. The price target of $124.77 was fulfilled within 1 day with a profit of $12.41 (11.04%) receiving and performance score of 110.45.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 01-Mar-2023
$124
$50.1 (67.79%)
$115
1 months 13 days ago
(16-Jan-2026)
10/13 (76.92%)
$39.17 (46.17%)
291
Hold Since 11-Sep-2024
$90
$16.1 (21.79%)
$77
4 months 20 days ago
(09-Oct-2025)
13/13 (100%)
$-0.78 (-0.86%)
298
Buy Since 10-Jul-2025
$121
$47.1 (63.73%)
$93
5 months 12 days ago
(17-Sep-2025)
5/6 (83.33%)
$25.64 (26.89%)
540
Buy Since 07-Sep-2022
$94
$20.1 (27.20%)
$94
11 months 12 days ago
(17-Mar-2025)
13/13 (100%)
$29.65 (46.08%)
317
Buy Since 28-Feb-2019
$83
$9.1 (12.31%)
$49
1 years 5 months 11 days ago
(18-Sep-2024)
12/12 (100%)
$21.95 (35.95%)
597
What Year was the first public recommendation made by Scott Henry?